During the corresponding time, Icon Plc recorded a revenue increase by 7.29 % year on year, sequentially revenue grew by 5.06 %. While revenue at the Icon Plc's corporate clients
Icon Plc's Comment on Sales, Marketing and Customers
ICON provides services to the pharmaceutical and biotechnology industries, including clinical development, functional outsourcing, and laboratory services. Their clinical development offerings encompass all phases (I-IV), peri- and post-approval stages, data solutions, and site and patient access services. Laboratory services include bioanalytical, biomarker, vaccine, GMP, and central laboratory services. ICON has established relationships with many leading pharmaceutical and biotech companies worldwide. The company has acquired Oncacare Limited, a global network of oncology research sites specializing in patient recruitment and clinical research delivery; KCR S.A Group, a contract research organization offering clinical trial services; HumanFirst, Inc., a life sciences technology company; and BioTel Research, LLC, a provider of medical imaging and cardiac safety monitoring services.
Investors Allege Misconduct in Class Action Lawsuit Against ICON Public Limited Company By April 8, 2025In a significant legal development, ICON Public Limited Company (NASDAQ: ICLR), a prominent player in the clinical research field, finds itself embroiled in a class action securities lawsuit. The legal proceedings, initiated by the law firm Levi and Korsinsky, LLP, are aimed at seeking financial recovery for investors who claim to have suffered losses related to their investments in the company. This lawsuit raises critical questions about the financial transparency and fiduciary responsibilities of ICON.The legal complaint, which was publicly disclosed on April 7, 2025, and followed a previous announcem...
As the ongoing landscape of investment litigation unfolds, the Rosen Law Firm, a respected name in the realm of investor rights, has issued a critical reminder for shareholders of ICON plc (NASDAQ: ICLR). The firm is calling attention to a pending securities class action that targets purchasers of ordinary shares during a specific timeframe from July 27, 2023, to October 23, 2024. The key date for affected investors to note is April 11, 2025, which marks the deadline to secure lead plaintiff status in this legal proceeding.Securities class actions typically arise when investors believe they have been misled by a company s statements or omissions regarding financial performance or business practices. In thi...
In the ever-volatile world of financial markets, the unexpected can turn a promising investment into a disheartening experience in the blink of an eye. Recent developments surrounding ICON Public Limited Company (NASDAQ: ICLR) have left many investors feeling the sting of losses, and now, a class action lawsuit is casting a spotlight on potential recovery options.As of February 24, 2025, the share price of ICON stands at $201.39. However, this figure comes amid a backdrop of concern, as the company s stock performance has struggled significantly in the year-to-date. When compared to the CSIMarkets index which tracks key suppliers ICON s stock has shown a noticeable dip. The current year has seen ICON shares ...
ICON: Leading the Charge in Clinical Research and Corporate Social Responsibility DUBLIN, March 2024 In a series of significant recognitions, ICON plc (NASDAQ: ICLR) has solidified its standing as not only a leader in clinical research but also as a paragon of corporate responsibility. This dual recognition underscores the company s commitment to excellence within the pharmaceutical and biotechnology sectors, and highlights its ongoing dedication to social and environmental sustainability. A Rising Star in Clinical ResearchOne of the most notable commendations for ICON came from the prestigious CRO Leadership Awards 2024. These awards celebrated ICON s outstanding capabilities in several critical areas o...
Icon Plc’s Comment on Sales, Marketing and Customers
ICON provides services to the pharmaceutical and biotechnology industries, including clinical development, functional outsourcing, and laboratory services. Their clinical development offerings encompass all phases (I-IV), peri- and post-approval stages, data solutions, and site and patient access services. Laboratory services include bioanalytical, biomarker, vaccine, GMP, and central laboratory services. ICON has established relationships with many leading pharmaceutical and biotech companies worldwide. The company has acquired Oncacare Limited, a global network of oncology research sites specializing in patient recruitment and clinical research delivery; KCR S.A Group, a contract research organization offering clinical trial services; HumanFirst, Inc., a life sciences technology company; and BioTel Research, LLC, a provider of medical imaging and cardiac safety monitoring services.
Sources:
Icon Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Icon Plc’s corporate clients.
For your research, we’ve provided 9 tables on Icon Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
6.98 %